APC |
antigen-presenting cell |
ARG1 |
Arginase 1 |
B2M |
β2-microglobulin |
cHL |
classical Hodgkin’s lymphoma |
CTL |
cytotoxic T lymphocyte |
CAF |
cancer-associated fibroblast |
DC |
dendritic cell |
DLBCL |
diffuse large B cell lymphoma |
DNMTi |
DNA methyltransferase inhibitor |
EZH2 |
enhancer of zeste homolog 2 |
FDA |
Food and Drug Administration |
FasL |
factor-related apoptosis antigen ligand |
FL |
follicular lymphoma |
HNC |
head and neck cancer |
HNSCC |
head and neck squamous cell carcinoma |
H3K27me3 |
histone h3 lysine 27 tri-methylation |
ICB |
immune checkpoint blocker |
ITIM |
immunoreceptor tyrosine-based inhibitory motif |
ITSM |
immunoreceptor tyrosine-based switch motif |
ILC |
innate lymphoid cell |
IDO |
indoleamine 2,3-dioxygenase |
IFN |
interferon |
iNOS |
inducible nitric oxide synthase |
JAK |
Janus kinase |
LSD1 |
lysine-specific histone demethylase 1 |
LAG-3 |
lymphocyte activation gene 3 |
MHC |
major histocompatibility complex |
MAPK |
mitogen-activated protein kinase |
mCRPC |
metastatic castration-resistant prostate cancer |
mAb |
monoclonal antibody |
MDSC |
myeloid-derived suppressor cell |
NK |
natural killer cell |
NSCLC |
non-small cell lung cancer |
NCI |
National Cancer Institute |
NF-κB |
nuclear factor kappa-light-chain-enhancer of activated B cells |
PD-1 |
programmed cell death receptor 1 |
PD-L1 |
programmed cell death ligand 1 |
PD-L2 |
programmed cell death ligand 2 |
PRC2 |
polycomb repressive complex 2 |
PTEN |
phosphatase and tensin homolog |
RT |
radiotherapy |
STAT1 |
signal transducer and activator of transcription 1 |
TDLNs |
tumor-draining lymph nodes |
TME |
tumor microenvironment |
TCR |
T cell receptor |
TAM |
tumor-associated macrophage |
TNF-α |
tumor necrosis factor α |
Th1 cell |
T helper 1 cell |
Treg |
regulatory T cell |
TGF-β |
transforming growth factor β |
TREM2 |
triggering receptor expressed on myeloid cells 2 |
TIM-3 |
T-cell immunoglobulin mucin 3 |
UC |
urothelial carcinoma |
VEGF |
vascular endothelial growth factor |